Erdafitinib, a selective FGFR inhibitor, has been reported to reverse T cell exclusion in immune-excluded tumor types by blocking FGFR signaling from CAFs, thereby enhancing the effect of anti-PD-1 [26]. The gene discussed is PDCD1; the disease is neoplasm.